Armata Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGArmata Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 56), indicating performance broadly in line with the market. Earnings contraction of 17% provides fundamental context to the price action. Investors should exercise caution due to high volatility (98% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.31 | -11.66% | BELOW |
| 50 SMA | $8.76 | -26.23% | BELOW |
| 100 SMA | $9.33 | -30.78% | BELOW |
| 150 SMA | $8.35 | -22.61% | BELOW |
| 200 SMA | $7.35 | -12.10% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARMP in an uptrend right now?
ARMP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ARMP overbought or oversold?
ARMP's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.
Is ARMP outperforming the market?
ARMP has a Relative Strength (RS) Rating of 56 out of 99. ARMP is performing about average compared to the market.
Where is ARMP in its 52-week range?
ARMP is trading at $6.46, which is 40% of its 52-week high ($16.34) and 32% above its 52-week low ($1.85).
How volatile is ARMP?
ARMP has a Beta of 0.95 and 52-week volatility of 98%. It's less volatile than the S&P 500 - generally more stable.